Wang Kai (Senior Scientist) is a professor, chief physician and doctoral supervisor. He is currently the President of the Fourth Hospital of Zhejiang University School of Medicine, the leader of Respiratory Medicine Center / Lung Tumor Center - Discipline, and the leading health talent of Zhejiang Province. He is also the editorial board member of Cancer Letters, the director-designate of the Lung Cancer Special Committee of Zhejiang Anti-Cancer Association, and the deputy director of the Respiratory Disease Branch of Zhejiang Medical Association. He is mainly engaged in clinical and basic research on immunotherapy of lung cancer. He discovered for the first time that IL-15 can induce high thiol expression in NK cells and enhance the tolerance of NK cells to oxidative stress through the activation of thioredoxin system, thus enhancing the therapeutic effect on lung cancer; led the national phase I/III multicenter clinical study of the national class I new drug mevalatinib, and found that mevalatinib is the preferred treatment option for patients with combined EGFR-sensitive mutations. He has undertaken 2 major projects of national new drug creation, 4 projects of National Natural Science Foundation of China and many other projects in Zhejiang Province, and published many high-quality papers in international famous journals such as J. Clin. Investig, Nano today and Lancet Respiratory Medicine.
